--- title: "A paralyzed man now picks up strawberries—thanks to a Chinese brain implant" date: 2026-09-25 category: Brain–Computer Interface site: NeuroAI canonical: https://neuroai.site/a/na-bci-rehab-china language: en --- # A paralyzed man now picks up strawberries—thanks to a Chinese brain implant > A Beijing-backed semi-invasive brain-computer interface called BeiNao-1 has reached nearly 30 implants, letting a tetraplegic patient pinch glass beads and lift a strawberry. We explain what changed, and how far the rehab claim really reaches. A man who had not moved his hands in years sat down, imagined closing his fist, and watched his own fingers curl shut. Months later he was pinching a glass bead between two fingers—and lifting a strawberry to his mouth. The bridge between his intention and his hand is a Chinese brain implant (脑机接口) barely the size of a coin. ## The device behind the story The system is **BeiNao-1 (北脑一号)**, a semi-invasive brain-computer interface (脑机接口) built by the Beijing Institute for Brain Disorders together with a local neurotech firm, Xinzhida. "Semi-invasive" is the crucial word: surgeons open a small skull window and lay a flexible electrode array on the **outside of the dura**—the protective membrane around the brain—without piercing the tissue itself. That trades a little signal sharpness for a much safer, lower-infection profile than fully implanted electrodes. The hardware is compact and wireless: a **128-channel** array that records neural signals and beams them out without a tether, which matters because a wire through the skin is a lifelong infection risk. ## What the trial actually shows BeiNao-1 entered a multi-center **registered clinical trial**—the formal NMPA-regulated path toward a medical-device license—on **31 March 2026**. The latest public figures, from Beijing municipal-science reporting and the institute itself, are: - **Nearly 30 human implants** (the device maker reported 27 by mid-June 2026) - **Longest implant exceeding 15 months** - **More than 70,000 cumulative safe operating hours** across patients - **System performance described as stable** throughout The anchor patient is a person with a spinal-cord injury who was tetraplegic—all four limbs inert. Before the implant he could not move his hands at all. After surgery, imagining a fist let the system detect the motor signal, stimulate the right muscles, and close the hand. At the one-year follow-up he could grip coarse objects, **pinch a glass bead with two fingers, and pick up a strawberry.** A second line of work targets speech: the same platform is decoding familiar Chinese words for patients with amyotrophic lateral sclerosis (ALS), reaching close to a hundred common terms. ## Why "semi-invasive" is the pragmatic bet Fully invasive implants that sit inside the brain capture the richest signals but carry the highest surgical risk and the hardest long-term safety questions. BeiNao-1's epidural route is the compromise China's clinicians are betting on for real wards, not lab demos: enough signal to drive meaningful movement, low enough risk to implant in fragile patients. The institute is also developing **BeiNao-2 (北脑二号)**, a fully invasive **512-channel wireless** system, for cases that need deeper resolution. Animal tests are done, and clinical validation is expected by the end of 2026. In monkey trials its decoding speed reached about **7.2 bits per second**, close to the roughly **7.3 bits per second** that Elon Musk's Neuralink has reported for its implant—a figure worth reading with care, since both numbers come from the companies themselves. ## The timeline to a real product This is still a trial, not a store shelf. The team aims to **finish enrolling patients in 2026** and **file for a Class III medical-device registration certificate in 2027**. A Class III certificate is the highest-risk category in China's device regime; clearing it would let the system be sold as a therapy rather than used only under research consent. Until then, every reclaiming of a strawberry is a data point from a small, carefully selected group—not a guarantee for the next patient who rolls into the ward. ## Honest limitations This article draws on People's Daily's national party-media platform, Beijing Municipal Science & Technology Commission reporting, and People's Daily Beijing, all covering BeiNao-1 and its lead researcher Luo Minmin. Keep these caveats in view: - **"World's highest level" and "global first" are the institute's own assessments**, not independent benchmarks we could verify. The 128-channel, semi-invasive claim is strong on paper; head-to-head international comparison is not something this article can confirm. - The trial is **ongoing and small**—roughly 27–30 implants. Anecdotes like the strawberry are powerful but are individual outcomes, not population statistics. - The **Neuralink comparison (7.2 vs 7.3 bits/sec)** uses figures each company has reported; methodologies differ and we could not normalize them. - The device is **not yet approved** for sale; 2027 is a planned filing date, not a granted license. Regulatory delay is possible. - We relied on Chinese institutional and state-media sources; we did not access the trial's peer-reviewed publication or the full NMPA filing. ## What readers can do now - **If you follow medtech,** track BeiNao-1's NMPA Class III filing in 2027—approval, not the demo, is the moment this becomes a reimbursable therapy. - **If you invest in neurotech,** separate "semi-invasive is safer" from "semi-invasive is proven"; watch enrollment completion in 2026 as the next hard milestone. - **If you care about the field's honesty,** read single-patient recovery stories as signal, not proof—ask for the trial size and the peer-reviewed record before believing the revolution has shipped. --- Published by NeuroAI (https://neuroai.site/) — https://neuroai.site/a/na-bci-rehab-china Free to quote with attribution and a link to the original.